Mitul Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitul Shah has a total of 289 co-authors. Here are the top co-authors by number of shared publications:
- Paul David Peter Pharoah
Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA
94 shared publications - Anna Jakubowska
Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
92 shared publications - James D. Brenton
University of Cambridge
92 shared publications - Jan Lubiński
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland
92 shared publications - Peter Andreas Fasching
Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
92 shared publications - Adelyn Bolithon
School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, Australia. 4
91 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Kaplan–Meier curves of OS in (A) main tumor groups (n = 582)—MBOT, MOC, LGI, and UGI; (B) patients with MOC by FIGO stage (n = 184); (C) patients with MOC by pattern of invasion in all stages (n = 178); and (D) patients with stage I MOC (n = 134), by pattern of invasion.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Kaplan–Meier curves of OS in (A) main tumor groups (n = 582)—MBOT, MOC, LGI, and UGI; (B) patients with MOC by FIGO stage (n = 184); (C) patients with MOC by pattern of invasion in all stages (n = 178); and (D) patients with stage I MOC (n = 134), by pattern of invasion.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis (n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis (n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Associations between gene expression and stage group and OS in MOC.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Associations between gene expression and stage group and OS in MOC.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Overall survival in MOC by pattern of invasion.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Overall survival in MOC by pattern of invasion.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Patient characteristics and analytical cohorts.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Patient characteristics and analytical cohorts.
- Open Access
Growth kinetics of high-grade serous ovarian cancer using longitudinal clinical data - implications for early detection
High-grade serous ovarian cancer (HGSOC) is the most lethal gynaecological cancer with patients routinely diagnosed at advanced stages with widespread disease. Evidence from screening trials indicates that early diagnosis may not reduce cancer-related deaths, possibly due to an underestimation of the true extent of the disease at screening. We aim to characterise the growth kinetics of HGSOC to understand why early detection has failed so far and under what conditions it might prove fruitful. We analysed a dataset of 597 patients with a confirmed HGSOC diagnosis, and identified 37 cases with serial CT scans. We calculated the growth rates of lesions in the ovaries/pelvis and the omentum and estimated the time to metastasis using a population-level Gompertz model. Finally, we simulated ultrasound and CA125 based screening in a virtual population of patients. Growing lesions in the ovaries and the omentum doubled in volume every 2.3 months and 2 months respectively. At both sites, smaller lesions grew faster than larger ones. The 12 cases with growing lesions in both disease sites had a median interval of 11.5 months between disease initiation and the onset of metastasis. Our simulations suggested that over 33% of patients would develop metastases before they could be screen detected. The remaining patients provided a median window of opportunity of only 4.7 months to detect the tumours before they metastasised. Our results suggest that HGSOC lesions have short time to metastasis intervals, preventing effective early detection using current screening approaches.
Open AccessGrowth kinetics of high-grade serous ovarian cancer using longitudinal clinical data - implications for early detection
High-grade serous ovarian cancer (HGSOC) is the most lethal gynaecological cancer with patients routinely diagnosed at advanced stages with widespread disease. Evidence from screening trials indicates that early diagnosis may not reduce cancer-related deaths, possibly due to an underestimation of the true extent of the disease at screening. We aim to characterise the growth kinetics of HGSOC to understand why early detection has failed so far and under what conditions it might prove fruitful. We analysed a dataset of 597 patients with a confirmed HGSOC diagnosis, and identified 37 cases with serial CT scans. We calculated the growth rates of lesions in the ovaries/pelvis and the omentum and estimated the time to metastasis using a population-level Gompertz model. Finally, we simulated ultrasound and CA125 based screening in a virtual population of patients. Growing lesions in the ovaries and the omentum doubled in volume every 2.3 months and 2 months respectively. At both sites, smaller lesions grew faster than larger ones. The 12 cases with growing lesions in both disease sites had a median interval of 11.5 months between disease initiation and the onset of metastasis. Our simulations suggested that over 33% of patients would develop metastases before they could be screen detected. The remaining patients provided a median window of opportunity of only 4.7 months to detect the tumours before they metastasised. Our results suggest that HGSOC lesions have short time to metastasis intervals, preventing effective early detection using current screening approaches.